We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+35.24%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.54B
AUM Growth
+$917M
Cap. Flow
+$107M
Cap. Flow %
3.03%
Top 10 Hldgs %
51.42%
Holding
131
New
31
Increased
26
Reduced
8
Closed
26

Top Buys

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$88M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$70.6M
3
BPMC
Blueprint Medicines
BPMC
+$30.6M
4
AMRN
Amarin Corp
AMRN
+$30M
5
TDOC icon
Teladoc Health
TDOC
+$26.6M

Top Sells

Rank Stock Value
1
SLDB icon
Solid Biosciences
SLDB
+$105M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$71M
3
ARGX icon
argenx
ARGX
+$53.9M
4
LJPC
La Jolla Pharmaceutical Company
LJPC
+$41M
5
XLRN
Acceleron Pharma
XLRN
+$39.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.08%
2 Miscellaneous 2.54%
3 Consumer Staples 0.8%
4 Financials 0.51%
5 Technology 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
101
Alnylam Pharmaceuticals
ALNY
$31.9B
– –
-262,241
Closed -$18.5M
AMED
102
DELISTED
Amedisys
AMED
– –
-3,672
Closed -$422K
ARGX icon
103
argenx
ARGX
$61.3B
– –
-560,941
Closed -$53.9M
CDNA icon
104
CareDx
CDNA
$2.72B
– –
-44,128
Closed -$1.04M
COLL icon
105
Collegium Pharmaceutical
COLL
$711M
– –
-445,000
Closed -$7.37M
DXCM icon
106
DexCom
DXCM
$32.6B
– –
-14,932
Closed -$442K
GKOS icon
107
Glaukos
GKOS
$10.1B
– –
-7,466
Closed -$417K
PEN icon
108
Penumbra
PEN
$12.5B
– –
-16,338
Closed -$2.04M
SAGE
109
DELISTED
Sage Therapeutics
SAGE
– –
-147,315
Closed -$13.1M
SIBN icon
110
SI-BONE Inc
SIBN
$831M
– –
-15,000
Closed -$307K
SLDB icon
111
CALL
Solid Biosciences
SLDB
$897M
– –
-122
Closed -$14K
SLDB icon
112
Solid Biosciences
SLDB
$897M
– –
-261,815
Closed -$105M
STAA icon
113
STAAR Surgical
STAA
$1.13B
– –
-12,953
Closed -$405K
STLA icon
114
Stellantis
STLA
$14.8B
– –
-62,000
Closed -$894K
TXMD icon
115
TherapeuticsMD
TXMD
$25M
– –
-30,000
Closed -$5.71M
WVE icon
116
Wave Life Sciences
WVE
$879M
– –
-59,498
Closed -$2.5M
XNCR icon
117
Xencor
XNCR
$1.77B
– –
-196,810
Closed -$6.83M
VCNX
118
DELISTED
Vaccinex, Inc. Common Stock
VCNX
– –
-238
Closed -$190K
IVC
119
DELISTED
Invacare Corporation
IVC
– –
-200,000
Closed -$860K
XLRN
120
DELISTED
Acceleron Pharma
XLRN
– –
-905,017
Closed -$39.9M
IMMU
121
DELISTED
Immunomedics Inc
IMMU
– –
-700,000
Closed -$11.3M
ADYX
122
DELISTED
Adynxx Inc
ADYX
– –
-19,122
Closed -$214K
CMTA
123
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
– –
-1,500,000
Closed -$17.6M
ZGNX
124
PUT
DELISTED
Zogenix, Inc.
ZGNX
– –
-200,000
Closed -$410K
LJPC
125
DELISTED
La Jolla Pharmaceutical Company
LJPC
– –
-4,313,611
Closed -$41M
1 2 3 4
5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q1 2019 Portfolio in Review

As of Q1 2019, Perceptive Advisors held 131 positions worth $3.54B, up 35% from $2.63B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Perceptive Advisors deployed $107M of net new capital in Q1 2019, opening 31 new positions and adding to 26 existing holdings. Its largest new stake was Array Biopharma Inc: 4,228,900 shares worth $103M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was Neurocrine Biosciences, an estimated $71M trimmed.

  • Perceptive Advisors's largest Q1 2019 buy was Array Biopharma Inc: 4,228,900 shares worth $103M.
  • Perceptive Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q1 2019, an estimated $70.6M increase.
  • Perceptive Advisors's biggest Q1 2019 reduction was Neurocrine Biosciences, cutting an estimated $71M.
  • Perceptive Advisors fully exited Solid Biosciences in Q1 2019, selling an estimated $105M.
  • Perceptive Advisors's ten largest holdings make up 51% of its $3.54B portfolio in Q1 2019.
  • Perceptive Advisors opened 31 new positions and closed 26 in Q1 2019.
  • Perceptive Advisors's portfolio value rose 35% quarter-over-quarter to $3.54B.

Based on Perceptive Advisors's 13F filing for Q1 2019, filed 15 May 2019.